… in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the
risk of mortality and heart failure (… , and the effects of dapagliflozin on these additional events. …

… a–d, Effects of dapagliflozin on the primary endpoint and its components. Effects of dapagliflozin
versus placebo at 12 weeks on KCCQ-CS (a), KCCQ-TS (b), KCCQ-physical limitations …

… Therefore, in the present report, we examined the effects of dapagliflozin according to an …
Collectively, these findings suggest that the substantial effects of dapagliflozin are incremental, …

… randomized controlled trials investigating the effects of dapagliflozin in heart failure patients.
… This meta-analysis only included clinical trials studying the effects of dapagliflozin and …

… heart failure event, defined as a worsening heart failure event (hospitalization or an urgent
visit resulting in intravenous therapy for heart failure) or … The effects of dapagliflozin, compared …

… Heart failure (HF) with mildly reduced and preserved ejection … Our findings confirm these
beneficial effects of dapagliflozin … to assess the effects of dapagliflozin on clinical outcomes …

… the rapid effects of dapagliflozin in heart failure with reduced … morbidity and mortality benefits
in heart failure (HF) with reduced … energetics and arrhythmic effects of dapagliflozin in type 2 …

… Type 2 diabetes mellitus (T2DM) is a major cause of heart failure (HF), both with reduced
ejection … Findings of a large clinical trial to evaluate the effects of dapagliflozin, another SGLT2 …

Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

… in patients with heart failure with preserved … heart failure with preserved ejection fraction)
[12] trials are awaited to ascertain the possible beneficial effects of empagliflozin in heart failure …